|
|
 |
| SERVICES - OTHER TESTS |
 |
|
ClearPath Diagnostics offers a variety of special tests to enable our clients to provide the highest quality patient care.
HPV
ThinPrep® Pap specimens and specimens collected with the Digene Cervical Sampler are approved for testing with Digene Hybrid Capture 2® DNA Assay. ThinPrep Pap specimens must be less than three weeks old. There must also be sufficient quantity remaining after processing the Pap smear to perform the HPV testing. Also, tissue specimens (paraffin embedded) can be tested for high and low risk HPV using the in situ hybridization. Tissue specimens are stable indefinitely. HPV testing can be done reflexively on all ThinPrep Pap smears. A request for HPV testing can be sent with the cytology request for a Pap smear on a ThinPrep specimen. For tissue specimens, check the "HPV Tissue Exam" section of the specimen requisition. HPV results are typically available within five days of specimen collection.
GC/Chlamydia
We offer testing for GC and Chlamydia (Neisseria gonorrhoeae and Chlamydia trachomatis) using the highly sensitive Gen-Probe® APTIMA Combo 2® Assay. This test can be done using the ThinPrep liquid Pap specimen that is also sent for Pap cytologic analysis. This method allows us to provide up to four results (Pap, HPV, and GC/Chlamydia) from a single specimen, minimizing specimen handling for collection and transportation. To do this test on the ThinPrep specimen, it must be ordered along with the Pap. Specimen collection and transport information for GC and Chlamydia testing can be found here.
In addition to ThinPrep Liquid Pap specimens, the assay can also be performed on urine specimens (female and male) and endocervical and male urethral swab specimens. We provide the collection and transport material.
AffirmTM
We offer triple testing using Becton Dickinson Affirm VPIII to differentiate and identify three vaginitis pathogens: Candida species, Gardnerella Vaginalis, and Trichomonas Vaginalis. This analysis requires a separate vaginal swab. We provide the special swabs and transport system for this test.
UroVysion®
We offer the Vysis UroVysion test for superior non-invasive assessment of patients with hematuria suspected of having bladder cancer and patients requiring subsequent monitoring for recurrence following previously diagnosed bladder cancer. This in situ immunofluorescent technique combines genomic DNA probe analysis with direct morphologic observation and provides greater sensitivity with fewer false negatives. Results are either positive or negative; there are no atypical, suspicious diagnoses.
Immunohistochemistry
We offer a full array of state-of-the-art immunohistochemistry markers. This specialized study of tissue and cells is presented to establish diagnoses with full histology technical support. It can be provided with interpretation as a consultation case or without as technical only services. Click here for a list of available immunostains.
In Situ Hybridization (HPV and Her-2/neu)
In situ hybridization is done on tissues to detect human papilloma virus and to determine the presence or absence of Her-2/neu gene amplification in breast cancer. In situ hybridization for detection of low and high risk human papilloma virus (HPV) is performed on formalin fixed, paraffin embedded tissue. The technique allows for specific nuclear localization of HPV DNA by light microscopy. In situ hybridization also is done for detection of Her-2/neu gene amplification. This technique utilizes fluorescence microscopy to determine the number of Her-2/neu genes in nuclei compared to the absolute chromosome 17 copy number. A ratio of greater than 2.0 indicates Her-2/neu amplification. A list of our available in situ studies can be found here.
|
|
|
|
|
